Project Grant R43GM149094
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$305K
Federal Agency
National Institute of General Medical Sciences
Awardee
Daxor Corporation (QGB8LQAGTAH8)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) federal grant program, aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered under this $455,000 award, with a project period from January 1, 2025 to November 30, 2029, include: Development of an AI-guided early sepsis identification tool for rapid diagnosis. Conducting sepsis phenotyping...
This National Science Foundation (NSF) Computer and Information Science and Engineering (CISE) Federal Grant Award (CFDA 47.070) provides $1,200,000 to the University of California, San Diego (UCSD) to develop advanced foundation models and algorithms for early detection of sepsis using clinical time series data. The 4-year project aims to create innovative technologies, including a new transformer-based model and optimization techniques, to accurately and efficiently process complex clinical...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $412,250 to Arizona State University to develop a continuous, real-time, automated smart catheter analyzer for early identification of sepsis through urine biomarkers. The device aims to enable clinicians to quickly respond and support heart and lung function for patients at risk of sepsis-related organ failure. The 2-year R61 (Phase I) project will design and...
This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...
The National Institute of General Medical Sciences (NIGMS) awarded a $312,974 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) federal grant program to the University of California, San Diego (UCSD) on February 1, 2025. The goal of this 5-year grant is to develop accurate, efficient, and interpretable multi-modal foundation models for the early detection of sepsis, a life-threatening condition. UCSD plans to address key challenges in this endeavor, including the...
This $186,221 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapies for pediatric patients. The key objectives are to: Augment sepsis phenotypes by incorporating high-frequency physiological data to identify additional subtypes and predict disease progression. Retrospectively develop and externally validate predictive algorithms to identify...
This Project Grant award of $298,646 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a rapid diagnostic test for sepsis-causing pathogens at Anvil Diagnostics Inc., a minority-owned small business in Cambridge, MA. The proposed DNA-based technology aims to comprehensively identify and quantify a broad range of pathogens in plasma samples using digital PCR hardware, providing results within 4 hours from small...
The National Institute of General Medical Sciences (NIGMS) awarded a $350,000 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Medosome Biotec LLC, a for-profit limited liability company. The grant, awarded on September 12, 2024, will support research and development to evaluate the safety and therapeutic potential of dichloroacetate (DCA) as a treatment for sepsis. Medosome Biotec will collaborate with researchers at the University of Florida, Wake...